Company intelligence / Profile preview

BioNovion

Ownership: Private
Development stage: Phase 2

Overview

BioNovion developed antibody discovery technology that was integrated into Aduro Biotech's portfolio after acquisition. The company's founders were involved in the discovery of pembrolizumab (Keytruda), an anti-PD-1 immune checkpoint inhibitor.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

3 assets

CRS-207

Phase 2

Indications: Mesothelioma, Ovarian cancer, Gastric cancer

2 more assets in the full pipeline.

Request access →

Partnerships

Dutch Cancer Institute (NKI-AVL) in AmsterdamDana-Farber Cancer Institute in Boston, MA

Beyond the preview

Go deeper on BioNovion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioNovion.

Explore the full profile